Doebele R, et al. Efficacy and safety of entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC). IASLC 2018; abstract OA02.01.
Omalizumab vermindert jeuk gerelateerd aan checkpointremmers en anti-HER2-therapieën
jun 2021 | Borstkanker, Immuuntherapie, Longoncologie, Uro-oncologie